Ascendis Pharma A/S reports results for the quarter ended in June - Earnings Summary

Ascendis Pharma A/S

10/08/2022 22:27

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.46​​ per share for the quarter ended in June. The mean
expectation of twelve analysts for the quarter was for a loss of
€2.13 per share.
    * Revenue rose 502.7% to €6.16 million from a year ago;
analysts
expected €5.81 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.46​.
    * The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * Ascendis Pharma A/S shares had risen by 0.2% this
quarter and
lost 30.8% so far this year.
    * The company reported a quarterly loss of €81.32 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $154.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:27 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -2.13          -1.46          Beat
 Mar. 31 2022      -2.00          -2.21          Missed
 Dec. 31 2021      -2.34          -1.87          Beat
 Sep. 30 2021      -2.29          -1.47          Beat